Key facts
- This page summarizes Robert A. Michael's Form 4 filing for AbbVie Inc. (ABBV).
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 Mar 2024, 17:50.
Robert A. Michael - 28 Feb 2024 Form 4 Insider Report for AbbVie Inc. (ABBV)
- Reporting relationship
- PRES & CHIEF OPERATING OFFICER
- Issuer ticker
- ABBV
- Reported as of
- 28 Feb 2024
- Net transaction value
- -$18,890,783
- SEC form
- 4
- Accepted by SEC
- 01 Mar 2024, 17:50:42 UTC
- Prior SEC filing
- 20 Feb 2024
- Next SEC filing
- 18 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- T.O. Odutayo, attorney-in-fact for Robert A. Michael
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert A. Michael filed Form 4 for AbbVie Inc. (ABBV) on 01 Mar 2024.
Change
- Previous filing in this sequence was filed on 20 Feb 2024.
- Current net transaction value: -$18,890,783.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABBV
transaction
Common Stock, $0.01 par value
Tax liability
- Transaction value
- $6,736,826
- Shares
- -37,638
- Change %
- -20%
- Price
- $178.99
- Shares after
- 145,964
- Date
- 28 Feb 2024
- Ownership
- Direct
ABBV
transaction
Common Stock, $0.01 par value
Options Exercise
- Transaction value
- $700,731
- Shares
- +11,420
- Change %
- +7.8%
- Price
- $61.36
- Shares after
- 157,384
- Date
- 29 Feb 2024
- Ownership
- Direct
ABBV
transaction
Common Stock, $0.01 par value
Options Exercise
- Transaction value
- $556,280
- Shares
- +10,140
- Change %
- +6.4%
- Price
- $54.86
- Shares after
- 167,524
- Date
- 29 Feb 2024
- Ownership
- Direct
ABBV
transaction
Common Stock, $0.01 par value
Sale
- Transaction value
- $3,804,046
- Shares
- -21,560
- Change %
- -13%
- Price
- $176.44
- Shares after
- 145,964
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
ABBV
transaction
Common Stock, $0.01 par value
Sale
- Transaction value
- $8,349,911
- Shares
- -47,319
- Change %
- -32%
- Price
- $176.46
- Shares after
- 98,645
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABBV
transaction
Derivative
Option (Right to Buy)
Options Exercise
- Transaction value
- $700,731
- Shares
- -11,420
- Change %
- -100%
- Price
- $61.36
- Shares after
- 0
- Date
- 29 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,420
- Exercise price
- $61.36
- Footnotes
- F3
ABBV
transaction
Derivative
Option (Right to Buy)
Options Exercise
- Transaction value
- $556,280
- Shares
- -10,140
- Change %
- -100%
- Price
- $54.86
- Shares after
- 0
- Date
- 29 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,140
- Exercise price
- $54.86
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.39 to $176.57, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.42 to $176.60, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.